Recent Updates
Recently added Catalysts

ciclosporin

Phase 3

Severe Atopic Dermatitis | Small molecule | Immunology |Novartis AG|Last Updated: Nov 2, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials2
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00232063Long-term Study of Ciclosporin for Atopic DermatitisPHASE3 COMPLETED -May 1, 2004 -Nov 2, 2011 -
NCT00232076Verification Study of Ciclosporin for Atopic DermatitisPHASE3 COMPLETED -May 1, 2004 -Nov 2, 2011 -
Unlock Drug Trial Details
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
ciclosporinDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 64 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * \- Appropriate the definition/diagnosis criteria of atopic dermatitis of the Japanese Dermatological Association * Patients with severest atopic dermatitis \[according to the "Guidelines for Treatment of Atopic Dermatitis 2002, the severity of atopic dermatitis will be classif...

Unlock Eligibility Criteria